Stay updated on FLT3 Inhibitor Combo in AML Clinical Trial
Sign up to get notified when there's something new on the FLT3 Inhibitor Combo in AML Clinical Trial page.

Latest updates to the FLT3 Inhibitor Combo in AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedAdded Revision: v3.3.3 to the page history and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check38 days agoChange DetectedFooter now displays Revision: v3.3.2, and the previous Revision: v3.2.0 entry was removed.SummaryDifference0.0%

- Check45 days agoChange DetectedThe notice about government funding and operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check66 days agoChange DetectedNo substantive changes to the study record; the screenshots show only administrative version updates (e.g., status and contact/location entries). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check88 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference7%

- Check95 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.2%

Stay in the know with updates to FLT3 Inhibitor Combo in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FLT3 Inhibitor Combo in AML Clinical Trial page.